clinical trial

[Oncoimmunology] Scientists used human U2OS osteosarcoma cells for the in vitro assessment of immunogenic cell death and established several in vivo models of melanoma in mice.

[Surface Oncology] Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced the first patient has been dosed by GlaxoSmithKline in the Phase I study of GSK4381562 in patients with solid tumors.

[ReAlta Life Sciences, Inc.] ReAlta Life Sciences, Inc. announced FDA clearance of an investigational new drug application for a Phase II clinical trial of RLS-0071 in neonates with hypoxic-ischemic encephalopathy.

[Neuroplast] Neuroplast has enrolled its first patient in a Phase II clinical trial to evaluate efficacy of its transformative Neuro-Cells® treatment that aims to prevent further damage to the central nervous system after sustaining acute traumatic spinal cord injury.

[Biochemical Society Transactions] Investigators provide a comprehensive overview of physiologically conserved or novel mechanisms utilized by tumor cells to reduce MHC-I or MHC-II expression.

[Clinical Cancer Research] Investigators appraise the existing literature and current clinical trial landscape of neoadjuvant therapies in HCC.